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Abstract: Executive function (EF) supports goal-directed behavior and includes key aspects such as
working memory, inhibitory control, cognitive flexibility, attention, processing speed, and planning.
Fragile X syndrome (FXS) is the leading inherited monogenic cause of intellectual disability and
is phenotypically characterized by EF deficits beyond what is expected given general cognitive
impairments. Yet, a systematic review of behavioral studies using performance-based measures is
needed to provide a summary of EF deficits across domains in males and females with FXS, discuss
clinical and biological correlates of these EF deficits, identify critical limitations in available research,
and offer suggestions for future studies in this area. Ultimately, this review aims to advance our
understanding of the underlying pathophysiological mechanisms contributing to EF in FXS and
to inform the development of outcome measures of EF and identification of new treatment targets
in FXS.
Keywords: fragile X syndrome; executive function; working memory; set-shifting; cognitive flexibility;
inhibitory control; attention; planning; processing speed
1. Introduction
Fragile X syndrome (FXS) is the leading inherited monogenic cause of intellectual disability,
resulting from >200 CGG trinucleotide repeat expansions in the 5′ untranslated region of the Fragile X
Mental Retardation 1 Gene (FMR1). The resulting hyper-methylation and silencing of FMR protein
(FMRP) production disrupts synaptic structure and function [1–5], leading to neural hyper-excitability
and atypical brain development. The characteristic phenotypic features in humans with FXS, including
impaired cognition, are hypothesized to be downstream effects of the altered neurodevelopment [6,7].
Because FXS is an X-linked genetic disorder, females with FXS are typically less severely affected than
males with FXS due to the variability of X-chromosome inactivation in females [8]. Thus, females
with FXS who demonstrate a greater degree of methylation and lower FMRP levels have a phenotype
more similar to males with FXS, whereas females with less methylation and greater FMRP levels
demonstrate more subtle clinical features. This is consistent with numerous documentations that the
severity of cognitive impairments are associated with the degree of methylation mosaicism and FMRP
expression in individuals with FXS [9–12], suggesting a progressive FMRP deficit leading to cognitive
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impairments. Yet, the precise mechanisms underlying specific cognitive impairments remain poorly
understood in FXS.
Executive function (EF), or a group of discrete cognitive abilities that support adaptive goal-directed
behavior [13], has been consistently documented as impaired in individuals with FXS, even beyond
what is expected given their general cognitive impairments (for examples, see [14–23]). Whether
this reflects a generalized deficit in EF or multiple deficits to specific EF domains (i.e., working
memory, response inhibition, cognitive flexibility, attention, planning, and processing speed) is
less clear. Previous studies using parent-report questionnaires have consistently documented high
rates of inattention and hyperactivity in FXS, but these studies have seldom used questionnaires
targeting a broader range of EF impairments or other questionnaires to assess additional EF domains
(for examples, see [24,25]). In contrast, previous studies using traditional neuropsychological and
experimental performance-based measures of EF have been able to capture deficits across all domains
of EF in individuals with FXS. Behavioral performance-based measures have a distinct advantage
over parent-report measures in their potential to be translated into tasks used during brain imaging
studies (i.e., functional magnetic resonance imaging (fMRI) or electroencephalogram (EEG)) or into
analogous versions to be used in studies of rodent models of FXS (i.e., FMR1 KO mouse). Further,
compared to parent-reports, performance-based measures are better able to objectively quantify
performance, which may help provide insights into the specific brain regions affected in FXS as
well as identify EF deficits that may be specific to FXS rather than those related to general cognitive
impairments and/or common comorbid diagnoses, like attention deficit/hyperactivity disorder (ADHD)
and autism spectrum disorder (ASD). Given previous indications of abnormalities in the frontostriatal
regions supporting EF in FXS (for example, see [26]), translational studies of EF offer great promise
for use as quantifiable biomarkers of brain function useful for early-phase drug development and
intervention trials.
Despite over 50 studies examining EF deficits in FXS using performance-based measures,
a comprehensive review of findings from males and females with FXS and their implications still
is needed (Table 1). Generally, previous studies of EF in FXS documented impairments across each
domain of EF relative to both chronologically age-matched (CA) controls and mentally aged-matched
(MA) controls, yet closer examination reveals key differences in performances depending on domain,
measure, task difficulty, sex, and/or control group studied. Understanding specific profiles of executive
dysfunction in FXS whose etiology may be distinct, yet overlapping, with that of general cognitive
impairments, is critical to understanding pathophysiological processes in FXS and developing novel
treatments for this patient population. Though EF impairments are major cause of distress for
individuals with FXS and their families [27,28] and poor EF leads to worse learning and academic
achievement outcomes [29,30], the development of behavioral and pharmacological interventions
aimed at improving EF have lagged behind those targeted towards other key phenotypes, like anxiety
and sensory hyper-sensitivity. Thus, a comprehensive review of previous studies is needed to
summarize EF deficits and their clinical and biological correlates in FXS, establish potential underlying
brain mechanisms of these deficits, and address critical limitations of previous studies. As more clinical
research begins to use EF as outcome measures in treatment trials, it is crucial to review previous
studies to guide future research studies examining EF in individuals with FXS.
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Table 1. Executive function measures and findings in individuals with FXS.
Executive Function Domain Measure 1 Findings 2 References
Working Memory Males Females
Verbal
WJ-III Memory for Words; NIH Tool Box List Sorting; RAKIT Learning Names;
WMTB Nonword Repetition; RBMT Story Recall; WMS-R Logical Memory I;
SB-IV Sentence Memory; Weschler Digit Forward, Digit Backward; WJ-III
Auditory Memory; WISC Letter-Number Sequencing; KABC Verbal Number
Recall; WISC, WAIS Arithmetic; TEA-Ch Elevator Counting
vs. CA ↓
vs. MA ↓
vs. iDD ↓
vs. DS ↓≈
vs. CA ↓
vs. IQ ≈
vs. Enviro ≈
[15,16,21,22,31–46]
Nonverbal/Visuospatial Leiter Spatial Memory; CANTAB Spatial Span; KABC Spatial Span; SB5 SpatialSpan; Delayed-no-matching-to-position; Toy Recall
vs. CA ↓
vs. MA ↓
vs. iDD ↓
vs. DS ↓≈
vs. CA ↓ [16,21,22,31,32,34,41,42,47–49]
Nonverbal/Visuoperceptual
Delayed-non-matching-to-sample; WMS-R Figural Memory I; Fish color;
Sequence Memory Task; n-back; SB-IV Bead Memory; Card Task; Hidden
Object Memory Test
vs. CA ↓
vs. MA ↓
vs. DS ↓≈
vs. MA ↓
vs. Enviro ↓≈ [15,16,34,35,37,43,49–51]
Inhibitory Control
Prepotent Response Inhibition KiTAP Go/No-go; Lab-TAB Snack Delay; Antisaccade; TEA-Ch Walk task
vs. CA ↓
vs. MA ↓
vs. iDD ≈
vs. DS ↓
vs. CA≈ [14,16,26,52–56]
Distractor Interference Stroop, Day/Night Task, CNT; Visual Selection; TEA-Ch Same-Opposite task;KiTap Distractibility, NIH Toolbox Flanker
vs. CA ≈↓
vs. MA ↓
vs. iDD ↓
vs. DS ↓
vs. IQ ↓≈
vs. Enviro ↓
vs. TS ≈
[16,22,31,34,35,52,55–60]
Cognitive Flexibility NIH Toolbox Dimensional Change Card Sort Test; CANTAB IED; WisconsinCard Sorting; iTap FlexiContingency Naming Task Subtest 3; Kbility
vs. CA ↓
vs. MA ↓
vs. iDD
vs. DS ↓≈
vs. PWS ≈
vs. Enviro ≈
vs. Enviro ↓≈ [15,22,23,31,32,34,35,46,48,55,56,61]
Attention
Sustained CPT; KiTap Vigilance; KiTAP Sustained Attention; WIAT Vigilance; WATTVigilan task; Elevator Counting
vs. CA ↓
vs. MA ↓
vs. DS ↓≈
n/a [15,16,37,50,52,56,62–64]
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Table 1. Cont.
Executive Function Domain Measure 1 Findings 2 References
Working Memory Males Females
Attention
Selective Symbol Search, Cancelation, Map Search, WATT Visearch task; WISC SymbolSearch; KiTAP Visual Scanning; TEA-ch Map Search
vs. CA ↓
vs. MA ≈
vs. DS ↑
vs. WS ↑
n/a [15,16,18,19,52,56,65]
Divided KiTAP Divided Attention; WATT Visearch dual task vs. MA ↓vs. DS ≈ n/a [16,56]
Planning NEPSY Tower; WJ-III Planning; CANTAB Stockings of Cambridge vs. MA ↓ n/a [22,31,32]
Processing Speed WISC Coding, Cancelation; NIH Toolbox Pattern Comparison; Reaction Timefrom CNT; KiTAP Alertness
vs. CA ↓
vs. MA ≈ vs. CA ↓ [22,31,33,35,56]
1 Abbreviations for cognitive measure used: CANTAB—Cambridge Neuropsychological Test Automated Battery [66], CNT—Contingency Naming Task [67], CPT—Continuous
Performance Test [68], IED—Intra-/Extra-Dimensional task, KABC—Kaufman Test of Attention Performance for Children [69], Lab-TAB—Laboratory Temperament Assessment
Battery [70], NEPSY—Developmental Neuropsychological Assessment, RAKIT—Revised Amsterdamse Kinder Intelligence Test, RMBT—Rivermead Behavioral Memory Test [71,72],
SB-IV—Stanford-Binet Intelligence Scale-4th Edition [73], SB-5—Stanford Binet Intelligence Scale-5th Edition, TEA-Ch—Test of Everyday Attention for Children [74], WAIS—Wechsler
Adult Intelligence Scale, WATT—Wilding Attention Tasks [75], WIAT—Wechsler Individual Achievement Test, WISC—Wechsler Intelligence Scale for Children [76], WJ-III—Woodcock
Johnson [77], WMS-R—Wechsler Memory Scale-Revised [78], WMTB—Working Memory Test Battery, Third Edition [79]; 2 ↓—indicates participants with FXS performed worse than
specified control group, ↑—indicates participants with FXS performed better than specified control group, ≈—indicates participants with FXS performed similar to specified control group,
≈↓—indicates mixed findings; Participant type: CA—chronologically-aged match controls, MA—mentally-aged matched control, iDD—control with idiopathic developmental delay,
DS—control with Down Syndrome, WS—control with William Syndrome control, PWS—control with Prader–Willi Syndrome, Enviro—environmental control (unaffected in-house relative).
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2. Methods
2.1. Search Strategy
To identify studies for inclusion in the review, computerized databases, including PubMed and
PsychINFO, were used to conduct searches. Keywords such as “Fragile X” AND “executive function”,
“working memory”, “inhibitory control”, “cognitive flexibility”, “set-shifting”, “attention”, “processing
speed”, or “planning” as well as variants on these terms were used. After collecting all available
peer-reviewed published articles, their reference sections were scanned to identify additional articles
that may have been previously missed. Authors of articles that were not available were contacted.
2.2. Selection Criteria
Broad inclusion criteria were used in order to provide the most comprehensive review of the
literature. The following criteria were used to determine whether an article could be included in
the review:
1. The paper was published in a peer-reviewed journal,
2. At least one participant sample had full mutation FXS,
3. Performance of individuals with FXS was compared against either a control population or
normative sample data OR performance of individuals with FXS is documented in the context of
a feasibility study,
4. At least one measure of EF was used,
5. The study reported quantitative scores (e.g., raw score, T-score, Standard score, etc.) beyond
completion rates,
6. EF was a primary or secondary research question, and
7. The study was not a case study.
2.3. Study Organization and Consolidation
The studies and corresponding measures were organized into six executive domains commonly
reported in the literature: working memory, response inhibition, cognitive flexibility, attention,
processing speed, and planning. In the first section, we summarized primary findings within each
executive function domain, separated by males and females (Table 1) and then in relation to clinical
and psychological variables. Next, we discussed current knowledge regarding neurobiology of EF
deficits in FXS by reviewing biological correlates, findings from studies using brain imaging and rodent
models, and potential pathophysiological mechanisms underlying these deficits. Finally, we addressed
critical considerations from previous studies and provide recommendations for future studies.
3. Review
3.1. Executve Function Deficits
3.1.1. Working Memory
Working memory is necessary for temporarily storing information for immediate use,
like remembering the homework assignment the teacher announced, and it often requires the
manipulation of that information, such as remembering to bring home the textbook needed for
the assignment. Theories propose a phonological loop aids in storage of verbal information, while a
visuospatial sketchpad aids in storage of visual-spatial or visual-perceptual information [80]. Here,
we discuss working memory measures based on the type of information needed to be retained: verbal
or nonverbal (i.e., spatial and perceptual).
Verbal working memory was the most common EF domain assessed across FXS studies, with the
majority of studies reporting impairments in males with FXS from school-age to adulthood compared
Brain Sci. 2019, 9, 15 6 of 29
to both chronological age (CA) and mental age (MA) control groups [15,17,22,31–41]. Among males
with FXS, the type of stimuli (i.e., words, digits) was less influential on performance than task difficulty,
or cognitive load, and this pattern emerged regardless of age. Cognitive load can depend on the amount
of information needing retention or the degree of manipulation of information needed. For example,
verbal working memory was relatively intact when cognitive load was low, like remembering two
to five words in forward order. In contrast, verbal working memory was significantly impaired in
males with FXS when cognitive load was high, like remembering the first word from two different
five-word lists [21,41,42]. This finding is consistent with studies documenting males with FXS had
a greater likelihood of hitting floor effects on higher load verbal working memory tasks [22,31,32].
Similar findings also arose in some studies comparing males with FXS to other syndromic participant
groups (e.g., individuals with Down syndrome (DS)). For example, males with FXS performed similar
to males with DS when working memory load was either very low (e.g., digit span forward; [17,41] or
very high (e.g., story retelling; [17]). This suggests both groups had relatively intact abilities when
working memory demands were low, whereas both groups were equally taxed compared to CA controls
under high working memory demand conditions. Yet, under moderate verbal working memory
conditions, males with FXS performed worse compared to males with DS, suggesting verbal working
memory deteriorated more rapidly with task difficulty in FXS than in DS. However, other studies do
not support this finding, and instead suggest task difficulty may have been less influential within
syndromic groups [15,35,47,48], warranting future studies that systematically vary difficulty to clarify
these inconsistencies.
With regards to development, two studies reported verbal working memory developed slower in
young males with FXS compared to CA controls even after accounting for mental age [36,50]. However,
in contrast, another study documented a narrowing gap in verbal working memory performance in
male and female children with FXS compared to a normative sample [33]. These contradictory findings
may be accounted, in part, by the presence of females in the latter sample. Alternatively, because
the narrowing gap was documented in an older sample of children (up to age 16 years), it also is
possible that verbal working memory performance in males with FXS developed more slowly during
early and middle childhood, then improved dramatically during adolescence. Visual inspection of
growth curves demonstrating a relatively flat maturation rate from 6–12 years, followed by a rapid
increase in performance beginning around 12 years confirmed this assertion [33]. Still prior studies
have documented impaired verbal working memory in adult males with FXS, suggesting that though
performance may become more similar to CA controls, it is nonetheless impaired. Overall, previous
studies of verbal working memory in males with FXS suggest performance is highly dependent on
cognitive load with more severe impairments as the amount of information is increased or when
manipulation is required and, to some extent, chronological age. However, verbal working memory
deficits may not be specific to FXS relative to other syndromic disorders.
With regards to nonverbal working memory, both visual–spatial (i.e., remembering the location of
an item) and visual–perceptual (i.e., remembering what item was previously shown) subdomains are
impaired in males with FXS relative to both CA and MA control groups [16,21,22,31,32,42,48]. As with
verbal working memory, performance depended on cognitive load, with relatively intact abilities
when demands were low, like remembering two locations in an array, but significantly worse abilities
compared to controls when demands were high, like remembering three locations on two different
arrays [21,42,49,51]. Notably, one study reported a relative strength in visual–perceptual compared to
visual–spatial working memory in males with FXS [48], suggesting the ability to remember what object
was shown is stronger than the ability to remember where the object was located. Young males with
FXS demonstrated slower development of nonverbal working memory compared to CA controls after
accounting for mental age [36,50], suggesting deficient growth of skills. Still longitudinal studies of
nonverbal working memory have not yet been completed in older children and adult males with FXS,
suggesting performance may improve more rapidly in later develop as seen in verbal working memory.
Most studies found that males with FXS performed similarly to other syndromic participant groups on
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measures of nonverbal working memory, [15,35,47,48] with some evidence of worse performance than
syndromic control groups during moderate level tasks [17,41] as found in studies of verbal working
memory. Taken together, this suggests verbal and nonverbal working memory deficits are present in
males with FXS across the lifespan that worsen with increased cognitive load, but are unlikely specific
to this syndromic population.
Few studies examined verbal and nonverbal working memory in females with FXS. Verbal
working memory performance was found to be impaired relative to CA controls [33,38] but relatively
intact compared to age- and IQ-matched [43] as well as environmental (i.e., unaffected family member)
control groups [34,39,40,44]. Though neither stimulus type nor cognitive load emerged as relevant
factors in performance. One study documented verbal working memory performance became more
similar to a normative sample from school age to late adolescence in females with FXS; however,
since males also were included in the sample, it is difficult to determine whether these developmental
findings occurred in one or both sexes [33]. Visual–spatial working memory abilities in females
with FXS also were impaired compared to CA controls, and unlike verbal working memory abilities,
seemed to depend on cognitive load as found in males with FXS [49,51]. For example, females with
FXS performed worse than CA controls when required to match the spatial position with that of
two trials ago (i.e., two-back) but similarly to controls when required to match with one trial ago
(i.e., one-back) [49]. With regards to visual-perceptual working memory, studies reported females with
FXS showed impairments relative to age- and IQ matched [43] and environmental control groups [34].
However, intact visual-perceptual working memory also has been documented compared to an
environmental control group [44]. With fewer studies completed in FXS females, inconsistent findings
make interpretations regarding verbal and nonverbal working memory less clear. Still previous
research suggests working memory performance may be more variable in females with FXS consistent
with their wide spectrum of general cognitive and adaptive abilities.
When comparing verbal and nonverbal working memory, some [32,36,42] but not all [41,51]
studies found verbal working memory to be a relative weakness compared to nonverbal working
memory in males with FXS, whereas the opposite pattern emerged in females with FXS [34,43,51].
For example, Pierpont and colleagues documented females with FXS outperformed males with FXS
on verbal working memory measures regardless of cognitive load [45]. The finding supports studies
documenting stronger expressive language skills in females with FXS compared to males with FXS [81]
as well as more consistent findings of nonverbal, as opposed to verbal, working memory impairments
in females with FXS. Though future studies are warranted to confirm these observations, as these
findings may have distinct treatment implications for males and females with FXS in terms of areas
targeted and strategies used.
3.1.2. Inhibitory Control
Inhibitory control refers to the ability to suppress contextually-inappropriate responses, and it is
critical for adapting behavior to changing and often uncertain environmental demands. Two distinct
cognitive components comprise inhibitory control: prepotent response inhibition (i.e., the ability
to withhold a previously reinforced behavior) and distractor interference (i.e., the ability to ignore
irrelevant information) [82], each of which have been evaluated in FXS.
Studies consistently documented reduced ability to withhold prepotent behavioral responses in
young male children with FXS compared to both MA and CA controls [14,16,52,53]. Fewer studies
have been conducted with older children and adolescent males with FXS, and findings have been
more inconsistent, demonstrating both intact [54] or impaired performance [55]. However, intact
performance only was reported relative to an age- and IQ-matched DD control group during an
fMRI task, suggesting cognitive and behavioral issues may have been less severe in this sample of
males with FXS since they were able to complete an fMRI session [54]. Thus, it is more probable that
prepotent inhibition deficits persists into adolescence in males with FXS, as supported by findings
from longitudinal and cross-sectional studies [14,52,55]. Prepotent inhibition errors also occurred at
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higher rates among males with FXS relative to both males with William Syndrome (WS) and males
with DS during school-age and adolescence [16,52]. This suggests withholding prepotent behavioral
responses may be more severely affected in FXS relative to other syndromic groups. Though whether
this reflects different developmental trajectories and/or persists into adulthood is unclear.
Impairments in distractor interference were documented from preschool-age to adulthood in
individuals with males with FXS compared to CA-, MA-, and IQ-matched control groups [16,22,31,
35,52,57] (but see [55] for null findings). This suggests difficulties inhibiting behavioral responses
to environmental distractors are present early in childhood and persist into adulthood in males
with FXS regardless of measure used (e.g., Stroop, Flanker). Findings that distractor interference
improved a rate similar to MA controls during early childhood suggest attenuated maturation of
underlying brain processes emerge early in development, but whether similar findings are observed
during later childhood to adulthood remains unclear. Comparisons with other syndromic populations
suggested distractor interference was relatively similar in males with FXS and males with WS [52] but
impaired compared to males with DS [16,35]. Though, the study of males with WS was completed
in preschool-age participants, whereas the studies of males with DS included school-age to adult
participants, suggesting inconsistencies may have emerged regarding differences in ages studied
or actual differences in the developmental trajectories of distractor interference. Taken together,
since males with FXS demonstrated impaired prepotent response inhibition and distractor interference
regardless of measure used (e.g., antisaccade, go/no-go), this suggests failure to inhibit behavioral
responses may be less dependent on task stimuli and complexity, thus making measurement selection
in future studies less constrained.
Only one study of prepotent response inhibition has been completed in females with FXS, in which
behavioral performance during an fMRI task was similar to that of female CA controls [26]. This
suggests inhibiting prepotent behavioral responses may be relatively intact in females with FXS,
though participant recruitment may have been biased towards less affected females due to using an
fMRI protocol. Studies assessing distractor interference in females with FXS also were equivocal,
with some findings of higher error rates during Stroop-like measures compared to environmental
controls and IQ-matched controls [34,57,58] and others of similar error rates to CA controls and
IQ-matched controls [59,60]. This suggests inhibiting responses towards distractors may be more
variable in females with FXS, consistent with their wider range of functioning and general cognitive
impairments. Of note, Tamm and colleagues’ observed females with FXS to have a similar distractor
interference error rate to CA controls, but they were slower to respond [60], suggesting some females
with FXS may have adopted a strategy to sacrifice speed for sake of accuracy. This cognitive strategy
to slow responses in order to improve poor inhibitory control was not observed in males with FXS,
suggesting this compensatory strategy may only be present in less affected individuals, like females
with FXS. Still, future studies are warranted to better understand potential compensatory strategies to
improve inhibitory control in males and females with FXS.
Though several studies examined both prepotent response inhibition and distractor interference
performance [16,52,55], no study to date has directly compared these abilities directly in individuals with
FXS. Thus, whether prepotent response inhibition or distractor interference is relatively more impaired
than the other or whether they both reflect a more general impaired process of behavioral inhibition is
not yet clear. Though Woodcock and colleagues documented impaired prepotent response inhibition
in school-aged/adolescent males with FXS relative to CA controls, but intact distractor interference [55],
it is important to note that authors used different variables for each measure. For example, error rate
was used to assess performance on the prepotent response inhibition measure and reaction time
was used to assess performance on the distractor interference measure. Thus, comparisons between
domains are less appropriate since they are quantifying difference aspects of inhibitory processes.
Furthermore, to our knowledge, no study to date has compared performance between males and
females with FXS. Hessl and colleagues [35] reported impaired performance on a distractor interference
measure in males and females with FXS relative to CA, DS, and iDD controls; however, results were
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not provided for each sex. Thus, clarifying patterns of deficits between prepotent response inhibition
and distractor interference as well as between sexes is needed and will be important for underlying the
discrete brain mechanisms disrupted in FXS as well as informing potential treatment targets.
3.1.3. Cognitive Flexibility
Cognitive flexibility refers to the ability to adaptively change behavior based on contextual
demands. This is most commonly assessed with dimensional sorting tasks in which participants are
required to switch from sorting figures based on one intra-dimensional feature (e.g., spatial location
on screen) or extra-dimensional feature (e.g., color or size) to another. Difficulty switching is most
commonly quantified by calculating the total number of trials to reach a specified criterion (i.e., higher
number indicates worse performance) or by number of categories achieved (i.e., lower number indicates
worse performance). However, several studies also calculated error rates, with a few categorizing errors
as either perseverative (i.e., continuing to choose previously correct responses despite feedback that it
is no longer correct), regressive (i.e., returning to the previously correct response after establishing the
new correct response), or distractor (i.e., choosing a never-reinforced or distractor response).
Across studies, males with FXS performed worse on cognitive flexibility measures compared
to CA and MA controls [22,31,32,35,48,55,83]. Deficits were observed from school-age to adulthood,
though error rates reduced with increasing MA in males with FXS [31]. Several studies also found
that impaired performance was predominantly due to increased perseveration errors [34,48,83].
This suggests individuals with FXS have difficulty shifting away from previously rewarded responses
and choosing new responses even after the previous response is no longer rewarded. This finding from
cognitive performance-based measures is consistent with findings from clinical-ratings that report
increased perseverate speech and behavior in individuals with FXS. Interestingly, Van der Molen
and colleagues [46] reported that perseverative responses were more prominent when cognitive
demands were low, whereas distractor errors were more prominent as cognitive demands increased.
This provides additional evidence that males with FXS have a perseverative response style, which may
reflect failure to disengage attention from a previously reinforced stimulus even when it is no longer
rewarded. Yet, when too many distractors were present, impaired distractor interference (an aspect of
inhibitory control) contributed to inflexibility, and thus attention was more readily diverted towards
irrelevant stimuli. This importantly demonstrates certain EF measures may require more than one
type of EF, and that individuals with FXS may be more disadvantaged during these certain measures
since multiple EF domains are disrupted.
Of note, Garner and colleagues reported absence of cognitive flexibility deficits in school-age
males with FXS relative to age- and IQ-matched controls during a modified version of the Wisconsin
Cart Sorting Task (WCST-M) created for individuals with cognitive impairments [61]. This suggests
cognitive flexibility may be intact relative to individuals of similar general cognitive impairments.
It also suggests the adapted versions of measures may be more appropriate for FXS participants,
and may reflect a better estimate of true cognitive flexibility skills as it requires less recruitment of
other EF domains. Inconsistent findings emerged comparing cognitive flexibility performance in
males with FXS relative to other syndromic groups, with some studies documenting more impaired
performance in males with FXS compared to males with idiopathic ID and males with DS [15] and
others documenting intact performance compared to these groups as well as males with Prader–Willi
Syndrome (PWS) [35,48,55]. Though these findings suggest deficits in cognitive flexibility may not
be specific to FXS, Van der Molen and colleagues conducted a discriminant analysis to classify error
types during a dimensional sorting task to differentiate groups and found that perseverative responses
differentiate males with FXS from DS and MA control groups [46]. Thus, though cognitive flexibility
impairments may not be specific to males with FXS, their perseverative response style may be unique
to this patient population, implicating a critical area to be further explored in future studies.
Few studies of cognitive flexibility have been conducted with females with FXS. Still, cognitive
flexibility deficits were documented in females with FXS relative to environmental controls [23,34],
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and like their male counterparts, these deficits predominantly emerged due to increased rate of
perseverative errors in one [34] but not the other study [23]. Thus, it is possible that a subgroup of
females with FXS may show cognitive flexibility deficits similar to those in males with FXS, though
more studies are needed.
3.1.4. Attention
Attention refers the ability to concentrate awareness with a specific behavioral or cognitive goal.
For example, sustained attention is needed to maintain general focus, selective attention is required
when concentrating on a specific information while ignoring other, and divided attention is used
when focus is required towards multiple goals. Across studies, a variety of measures were used
and quantified attention performance in different ways. The most common variables were: reaction
time (time to respond to target), hit rates (correct target identification), miss rates (omission of target
identification), and false alarm rates (incorrect target identification). Though most studies examined
visual attention towards visual stimuli, a few also examined auditory attention.
In school-aged males with FXS, sustained attention was found to be impaired relative to CA
and MA controls as they demonstrated both slower reaction times [16,50,52,62] and reduced hit
rates [50,62]. One study reported reduced reaction time in the absence of differences in hit rate [16],
suggesting some males with FXS may attempt to slow behavioral responses in order to perform
more accurately. Still this cognitive strategy to improve accuracy was not observed in other studies,
suggesting the majority of males with FXS may not slow responses at all or enough to be effective [50,62].
Sustained attention was impaired across both the auditory and visual domains, though males with FXS
demonstrated relatively weaker performance (fewer correct hits and fewer correct rejections) during
auditory compared to visual measures [62,63], consistent with findings of strong visual-perceptual
skills and disturbances in auditory processing in males with FXS [84]. School-age males with FXS
showed comparable performance to MA controls in one study that used a shorter version of a sustained
attention measure [63], suggesting males with FXS may be able to maintain attention for a specific
behavioral goal for a short duration (<5 min), but have greater difficulty when tasks require longer
durations of sustained attention. Additionally, relatively intact sustained attention also was reported
in males with FXS from 11–38 years, suggesting sustained attention may be less impaired in later
childhood into adulthood [37]. Longitudinal studies in young males with FXS reported sustained
attention developed at a slower rate compared to CA controls, but at a similar rate when adjusted
for MA [50]. Yet, whether gaps in performance relative to CA controls narrows with age remains
unclear. Previous studies reported sustained attention was similar among males with FXS and males
with DS [16,52], but stronger in males with FXS compared to males with WS [52] in terms of both hit
rates and reaction times. Taken together, previous studies have indicated consistent findings of poor
sustained attention among school-age males with FXS though performance may be less impaired when
tasks are shorter and with increasing age.
During selective attention tasks, previous studies have reported similar hit rates in males with
FXS relative to MA controls from toddlerhood to adulthood [15,18,50,52,65]. However, a few studies
documented worse performance compared to MA [16,19,65] and CA controls [19], especially under
certain conditions. For example, males with FXS had lower hit rates and increased errors when more
distractors were present and/or when distractors were more similar to target stimuli. A similar finding
was documented during studies of distractor interference, suggesting both selective attention and
inhibitory controls skills may be highly dependent on context of the environment. For example,
certain EF abilities are relatively intact in a less distracting and ambiguous setting for males with
FXS, but as the cognitive and neural processes supporting these abilities become more taxed, they are
more likely to make errors. Of note, multiple studies reported that males with FXS demonstrated
increased rates of perseverative responding during selective attention measures, or responding to the
same correct target multiple times even after the end of the trial [52,65]. This finding is consistent
with studies of cognitive flexibility and distractor interference that also reported a higher number of
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perseveration errors relative to all control groups. This suggests males with FXS demonstrated both
impaired ability to shift behavior and attention away from previously correct responses even in the
absence of reinforcement. Taken together, these findings indicate that a similar underlying cognitive
and neural mechanism may drive perseverative responding and/or failures to disengage. Further
evidence that this response style is specific to males with FXS comes from selective attention studies
demonstrating increased perseverative errors compared to both DS [18,52] and WS groups [19,52]
even when overall performance was similar across groups [18,19]. Yet, not all previous selective
attention studies categorized error types, suggesting additional studies are needed to confirm these
findings [16,19]. Though one study reported stronger selective attention performance in adult males
with FXS compared to adult males with DS [83], it is unclear whether this reflects greater improvements
in selective attention from adolescence to adulthood relative to individuals with DS or differences
in measures used [18]. Overall, previous studies noted relatively intact selective attention in males
with FXS across the lifespan that becomes impaired as task difficulty increases. Yet, the presence of
perseverative errors suggests a more subtle impairment in this area that may be related to other areas
of executive dysfunction as well as specific to FXS.
Only one study comparing divided attention performance to MA controls found fewer hits but
similar response times and rates of false alarms [16]. Authors also documented greater distance
moved when locating stimuli [16], which may account, in part, for the lower hit rate. More studies are
warranted in assessing divided attention in FXS. Studies examining attention in females with FXS are
needed to determine whether their profile of deficits is similar to those in males with FXS.
3.1.5. Planning
Planning is the ability to manage current and future goals and involves formulation, selection,
and execution of specific sets to reach those goals. Few studies have examined planning in individuals
with FXS, which may be, in part, due to prominent floor effects [32]. This suggests available planning
measures may be too difficult for individuals with FXS to complete and/or planning abilities are
significantly more impaired in FXS relative to other domains of EF. During a version of the Tower
of Hanoi task, school-age males with FXS were observed to achieve fewer correct trials compared to
MA controls, suggesting males with FXS had an impaired ability to plan or problem solve during
increasingly complex scenarios [22,31]. Still, future studies are warranted in this area, especially those
that include females with FXS, and studies utilizing tests with lower floors to measure performance of
a broader range of individuals. Additionally, assessment of error types may be useful in future studies
as has been found in measures of other EF domains.
3.1.6. Processing Speed
There is some controversy whether processing speed is an executive function or a cognitive
process that supports all executive functions (for example, see [85]). For the purpose of this review and
its relevancy in FXS, we include processing speed as a component of EF, using the more conservative
definition of simple reaction time [85]. Processing speed performance varied across studies but was
highly dependent on control group used. For example, males with FXS from school-age to adulthood
demonstrated longer reaction times compared to CA controls [33,35], but comparable reaction times
to MA, iDD, and DS control groups [22,31,35]. This is consistent with findings that reaction times
increased at a slower rate relative to CA [33] but at a similar rate relative to MA controls in FXS
males [31]. Longer reaction times also were observed for females with FXS relative to CA controls, but it
is unclear whether performance differs from MA controls [33,35]. Together, this suggests processing
speed is deficient compared to typical development, but impairments are likely not specific to FXS.
3.1.7. Behavioral and Psychological Correlates
Parent-report measures used to identify clinical relationships include those that exclusively
examined EF dysfunction (e.g., Behavior Rating Inventory of Executive (BRIEF)), those that contained
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subdomains related to EF impairment (e.g., hyperactivity subscale of the Aberrant Behavior Checklist
(ABC)), and those examining other aspects of behavior and function, like daily living skills. Most studies
demonstrated significant relationships between behavioral performance and parent-report measures,
though associations were not limited to the specific EF domain behaviorally assessed [14,35,56].
For example, impaired prepotent response inhibition was associated with parent-reports of inattention
and hyperactivity and impaired distractor interference was associated with parent-reports of inattention,
hyperactivity, stereotyped speech, and reduced adaptability to change [14,56]. Likewise, cognitive
flexibility related to attention problems and adaptability to change [56] and processing speed related to
hyperactivity, stereotyped speech, and reduced adaptability to change [56]. This extensive overlap
in parent-reported clinical presentation and behavioral performance has several implications. First,
it suggests that the EF domains captured in parent-report measures may not correspond well to
those domains examined using behavioral measures. For example, difficulty flexibly shifting away
from a previous behavioral response during a cognitive flexibility task may be reported by parents
as difficulty shifting attention. This also could mean that both or either lack discriminant validity,
reflecting measurement specificity issues. Second, the extensive overlap in symptoms may reflect
less differentiated brain processes underlying separate EF domains in FXS typically found in younger
typically developing children. It also may reflect multiple neural system dysfunctions. Lastly, it also
could suggest that behavioral measures used in studies are likely confounded by co-occurring conditions,
like ADHD, ASD, or anxiety. For instance, difficulties in sustained attention and cognitive flexibility
may interfere with performance during a Stroop-like task. Similarly, studies examining EF performance
in relation to ASD symptom severity provided consistent findings of more severe ASD symptomalogy
relating to worse EF deficits, which was relatively independent of domain [31,35,36,63,64]; (but see [38]
for null finding). Of note, Cornish and colleagues reported that poorer auditory, but not visual,
attention predicted more severe ASD symptoms 12 months later, suggesting auditory attention may be
an important risk marker for ASD in young males with FXS [64]. Future studies are needed to clarify
these relationships by directly comparing FXS participants with and without co-occurring diagnoses.
Additionally, since these studies examined correlations without controlling for MA or global IQ, it also
will be important for future studies to determine the extent to which some of these relationships are
driven by more general cognitive deficits than those related specifically to EF.
Additionally, adaptive behavior skills were related to inhibitory control as well as verbal and
nonverbal working memory in a co-ed FXS sample [35] and to inhibitory control in a female only
sample [59]. For example, working memory deficits could make performing self-care routines
challenging without visual reminders of necessary steps to bathing or brushing teeth. Likewise,
difficulty inhibiting prepotent behaviors may manifest as maladaptive coping behaviors or violations
of social norms. Yet, neither study found a relationship between cognitive flexibility and adaptive
behavior [35,59]. These findings begin to demonstrate that certain disrupted EF skills may have
downstream effects on adaptive skills necessary for daily living, suggesting interventions targeting EF
also may improve adaptive skills. Still more studies are needed in this area.
Importantly, EF abilities were predictive of later functioning as demonstrated by multiple studies.
For example, Pierpont and colleagues found that higher working memory performance in school-aged
males with FXS predicted greater rate of development of vocabulary and language skills two years
later [45]. This highlights that language acquisition in FXS is dependent on the ability to hold
verbal representations online as seen in typically developing youths, suggesting the importance of
interventions improving working memory in early childhood [86]. Though study authors did not
replicate this finding in females with FXS, this may be, in part, due to stronger baseline vocabulary
and language skills in females [45]. Additionally, better performance on sustained attention tasks was
found to be a strong predictor of lower teacher-rated hyperactivity and problem behaviors and greater
prosocial behaviors one year later in school-age males with FXS [50,62]. Likewise, better performance on
selective attention tasks in both auditory and visual domains predicted lower parent-reported ADHD
symptoms and higher nonverbal IQ 12 months later in school-age males with FXS [64]. This suggests
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intact early attention skills may be a protective factor against certain comorbid conditions in males
with FXS. Interestingly, higher parent-ratings of inattention during preschool years predicted greater
improvements in prepotent response inhibition at school-age in males with FXS [14]. Though this
finding seems counterintuitive, it suggests the malleability of EF in early development and that
weaknesses observed at one timepoint may be related to strengths at another timepoint. It also could
suggest that FXS participants with attention issues were identified early and provided treatment,
and thus greater improvements were seen across domains. Taken together, findings of relationships
between EF and multiple areas of functioning emphasize these skills are likely connected at the brain
level and develop very early in childhood. It also highlights the importance of EF in multiple areas of
functioning and that early treatment targeting EF may have important, long-lasting impacts.
3.1.8. Summary of EF Domain Findings
Few studies directly compared performance between EF domains in FXS, making it difficult to
determine whether a consistent profile of EF strengths and weaknesses is evident. This is critical to
better understanding whether certain EF deficits emerge as “syndrome specific” to FXS as suggested by
some groups [52,87]. Among child males with FXS, verbal working memory was a relative weakness
relative to processing speed [33]; however, among adult males with FXS, working memory emerged
as a relative strength compared to cognitive flexibility and planning [32]. These studies suggest that
working memory may shift from a relative weakness to a relative strength from childhood to adulthood,
consistent with findings that the observed gap between verbal working memory performances in FXS
and a normative sample narrows during adolescence [33]. A similar observation also was observed
in females with FXS with working memory as a relative weakness compared to processing speed
in childhood but becoming a relative strength compared to inhibitory control in adulthood [33,38].
This provides important evidence that EF profiles in FXS likely change over the course of development
in line with changes in brain maturation and potential compensatory mechanisms, a finding also
supported by differences in developmental patterns of specific EF domains in males and females with
FXS. For example, Cornish et al. [52] found that for children with FXS, selective and sustained attention
increased more with age compared to their inhibition skills, whereas inhibition skills increased more
than selective and sustained attention for children with Down syndrome. Additionally, whether
developmental and maturation changes also may differentiate males with FXS from females with FXS
across certain EF domains also remains unclear and warrants future studies.
Likewise, no study to date has compared strengths/weaknesses profiles across syndromic disorder.
Still it is important to note that individuals with FXS demonstrated distractor interference errors
during distractor interference and cognitive flexibility measures as well as perseveration errors during
distractor interference, selective attention, and cognitive flexibility measures [15,16,18,19,46,48,52,65].
This suggests these EF deficits may reflect underlying cognitive and neural abnormality that manifests
itself behaviorally in different contexts of uncertainty/difficulty. Additionally, since perseverative
responding was not observed as prominently in other syndromic developmental disorders, it also
suggests that perseverative errors may be specific to FXS, reflecting an inability to shift behavior or
attention away from a response that has been previously reinforced and/or reflect difficulty managing
multiple possible responses [88]. Thus, rather than being separate deficits in ‘inhibitory control’,
‘cognitive flexibility’, and ‘selective attention’, perseverative responding may represent a deficit in
a selective component process that impacts multiple EF domains and areas of functioning. As this
was one of the most consistent findings across studies, aside from documentation of the presence
of EF deficits beyond those expected given cognitive functioning, this warrants further attention in
future studies.
3.2. Neurobiology of EF Deficits in FXS
Establishing the extent to which deficits on EF measures relate to biologically-based substrates
(i.e., FMRP levels, brain anatomy) may provide critical insights into the pathophysiological mechanisms
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underpinning these cognitive deficits in FXS. Following a review of these findings from previous
studies, we will briefly address studies using translational models to assess for EF deficits in FMR1
Knockout (KO) rodents and then finally summarize potential pathways from gene to behavior.
3.2.1. FMRP
Several studies indicated lower peripheral FMRP expression was associated with more severe
EF deficits in both males and females with FXS [39,40,49,51], suggesting a progressive FMRP deficit
has a dose-dependent relationship with EF skills. For example, FMRP expression contributed up to
60% variance in EF performance in these studies, suggesting protein levels largely contributed to EF
dysfunction, though other neurobiological and environmental factors influence these deficits as well [40].
On the other hand, one study reported cognitive flexibility performance no longer related to FMRP
expression once FSIQ was controlled for in a co-ed sample [23]. Given the well-documented relationship
between FMRP levels and intellectual ability [8–11], it suggests general cognitive functioning may have
a stronger relationship with FMRP than specific EF skills, like cognitive flexibility. This finding also
may be due, in part, to less variation in FMRP levels in males with FXS despite a wider spectrum of
cognitive abilities. Thus, the link between FMRP levels and EF deficits may be more evident in females
only. Several studies of females with FXS reported that reduced FMRP expression was associated with
worse processing speed [39,40] and cognitive flexibility deficits related to lower X activation ratio [34],
which directly affects the amount of protein produced. In contrast, relationships between CGG repeat
count and EF measures largely were absent [34,47,83], consistent with other studies documenting CGG
repeat count is a less reliable biological correlate than FMRP levels. Still, FMRP levels themselves
remain limited as taken from blood samples, and thus are a less objective quantification of levels in the
brain. Together, these findings provided an important link between causal pathology and observed
phenotype of EF deficits in individuals with FXS.
3.2.2. Structural Brain Imagining Studies
Structural MRI studies consistently have reported increased volume of the caudate nucleus in
individuals with FXS [89–99]. The caudate is critical for goal-directed actions, whereby individuals can
successfully execute correct behavioral responses and appropriate subgoals [100]. Of note, abnormal
caudate volume has been associated with perseverative responding in a number of psychiatric
and neurological conditions (for examples, see [101–103]), suggesting its role in this behavior in
FXS. Caudate volumetric increases appear to occur early in development and persist throughout
the lifespan in FXS [96], consistent with findings documenting EF deficits, including perseverative
responding, are found from early childhood to adulthood in individuals with FXS. Furthermore, caudate
enlargement also has been found to be related to reduced FMRP expression, suggesting a possible
progressive dose-dependent relationship between protein and brain volume [92,95]. In conjunction
with similar findings of a relationship between reduced FMRP expression and more severe EF deficits,
this indicates a potential pathway from reduced FMRP leading to increased caudate to EF dysfunction.
Individuals with FXS also have demonstrated reduced volume of the cerebellar vermis [92,96,98,
104,105], a region with known involvement in working memory, cognitive flexibility, and planning [106].
On the other hand, inconsistent findings have emerged regarding cerebral volume in FXS, though
regional differences largely accounted for these inconsistencies [41,91,96,99]. For example, several
groups have found increased volume of parietal lobes [92,98] but reduced volume of frontal
lobes [94,98,99]. Frontal lobe involvement in EF has been widely-documented (for review see [107]),
thus it is not surprising FXS patients have demonstrated reduced volume in this region. The alterations
in the parietal cortex previously have been associated with failures to flexibly shift behavior in
ASD [108,109], suggesting it may contribute to these deficits in individuals with FXS.
Additionally, previous findings have found altered white matter tract circuitry in individuals
with FXS using diffusion tensor imaging [110]. The dorsal–prefrontal circuitry, which includes the
caudate, has prominent roles in working memory, set-shifting, and processing speed (for review
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see [111]). Haas and colleagues [112] also reported greater relative fiber density in the left ventral
frontostriatal pathway in young male FXS participants compared to both typically-developing and
developmentally-delayed controls. As these findings were observed as early as one year, this suggests
frontostriatal white matter tract abnormalities, like increased caudate volume, appear early in life and
thus likely reflect alterations in pre- or perinatal brain development. Together, this suggests abnormal
development of the frontal-striatum-parietal-cerebellum networks likely is involved in executive
dysfunction in FXS [26,113].
In a previous study, regional differences in caudate volume related to distinct behavioral
phenotypes. For example, the ventromedial caudate of the orbitofrontal cortex (OFC) was associated
with social abnormalities, whereas the dorsolateral caudate of the dorsolateral prefrontal cortex (DLPFC)
was associated with repetitive speech and behavior, aspects of impaired cognitive flexibility [89].
Though behavioral findings have implicated extensive overlap in neural structures responsible for
EF, this finding suggests subtle regional difference in neuroanatomical abnormalities may selectively
disrupt processes involved in certain areas of EF. It also may suggest that observed behavioral deficits
may arise from numerous neural abnormalities. For example, the OFC also is involved in reward
processing [114], which is important in dimensional sorting tasks of cognitive flexibility. Thus, high rates
of perseverative errors found in FXS may be maintained by both disruptions to reward processing in
OFC and propensity towards repetitive behavior in DLPFC. Still, more studies directly examining the
relationships between structural brain abnormalities and clinical phenotypes are needed.
3.2.3. Functional Brain Imaging Studies
Only a few functional brain imaging studies during EF measures have been completed in
FXS [26,49,54,60]. Though these studies differed in sample sex, control group, and EF domain, findings
consistently demonstrated that FXS patients show a pattern of reduced activation in frontostriatal
regions critical for EF. For example, during an n-back task of nonverbal working memory, females with
FXS did not exhibit expected increases in frontal activation when cognitive load increased, and this
reduced activation was related to worse working memory performance as well as reduced FMRP
expression [49]. A similar finding was observed in females with FXS during an inhibitory control task,
such that reduced FMRP expression related to both worse inhibitory control performance and greater
reductions in prefrontal cortical, basal ganglion, and hippocampal activation. Together, these findings
implicate the involvement of FMRP in the disruption of frontal-striatum-parietal-cerebellum circuitry,
and in turn, executive dysfunction. As this appears to be a progressive deficit with reduced FMRP
expression, the circuitry may be more disrupted and less able to appropriately modulate activity when
cognitive load increases. This assertion is further supported by several previous behavioral studies
discussed earlier, in which EF performance deteriorated as cognitive load increased (i.e., working
memory, selective attention).
Interestingly, several fMRI studies documented evidence of compensatory brain mechanisms
to support EF performance in males and females with FXS [26,54,60]. For example, Hoeft and
colleagues [54] found that during a go/no-go task of prepotent response inhibition, males with
FXS showed reduced right frontostriatal activation, but increased left ventrolateral prefrontal cortex
activation compared to both IQ-matched DD and CA controls. These findings occurred in the
absence of differences in behavioral performance, suggesting compensatory bilateral activation of
prefrontal regions may have improved abilities to withhold prepotent responses in males with FXS.
The authors also found that males with FXS who demonstrated greater activation in left ventrolateral
prefrontal cortex also had higher levels of FMRP expression. This provides further evidence of
the effect of progressive FMRP deficit on EF, suggesting the ability of the brain to develop and use
compensatory mechanisms only may be afforded to males with FXS with some FMRP production.
Consistent with these findings, previous fMRI studies also have documented that females with FXS
with higher levels of FMRP demonstrated increased compensatory activation with recruitment of
bilateral (versus left-lateralized) prefrontal regions during a distractor interference task [59]. Females
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with FXS demonstrated comparable errors to CA females, but reduced reaction times, suggesting they
also may have adopted a behavioral strategy to sacrifice speed for sake of accuracy. Though differences
in activation patterns for FXS and CA participants also may have been due, in part, to differences in
behavioral performance. Thus, several studies provide evidence that some individuals with FXS show
compensatory bilateral activation of regions known to support specific EF domains (i.e., prepotent
response inhibition, distractor interference, nonverbal working memory) that tracks not only with
better behavioral performance, but also with FMRP expression. Taken together, previous structural
and functional imaging studies provide critical insight into disrupted brain regions and circuitry that
likely contribute to EF deficits in FXS, though the specificity of these findings to FXS and selectivity to
distinct brain alterations and corresponding EF deficits remains unclear.
3.2.4. Potential Mechanisms Underlying EF Deficits in FXS
Together, this section has highlighted the potential critical links between FMRP, brain function,
and EF deficits in FXS. FMRP is required for normal dendritic pruning, and its absence can lead to
immature synapses, aplastic, and non-specific connections, and presumed aberrant activity within
affected structures [7,115,116]. The absence of FMRP is presumed to alter structural integrity of
neurons and lead to downstream aberrant neural connectivity [117]. This provides one potential
mechanism linking the FMR1 gene to executive dysfunction through disrupted development of
frontal-striatum-parietal-cerebellum circuitry. Still the precise processes underlying this developmental
cascade remains poorly understood. FMRP is expressed throughout the cerebral cortex, cerebellum,
hippocampus, and thalamus during embryonic development [118,119], suggesting its absence could
have widespread neural effects as demonstrated in behavioral findings. Regional differences in
volumetric findings may provide key insights into possible divergent trajectories in neurodevelopment.
For example, volumetric enlargements may indicate reduced post-natal synaptic pruning, as suggested
by findings of increased volume of caudate nucleus and of increased frontostriatal white matter tract
density as early as 1–3 years in males with FXS [112]. In contrast, volumetric reductions may indicate
pre-natal effects of deficient FMRP leading to disrupted post-natal maturation.
Additionally, imbalance of excitatory: inhibitory neural activity, including within PFC, repeatedly
has been documented in slice, rodent, and human models, yet its relation to cognitive deficits has been
sparsely investigated [120–122]. Enhanced gamma frequency activity in local circuits during rest and
disrupted evoked gamma oscillations have emerged as a relatively conserved and stable biomarkers of
neural hyper-excitability in translational models of FXS [123,124]. Gamma oscillations are generated
by local synaptic interactions of excitatory and inhibitory neurons and controlled by rhythmic firing of
inhibitory interneurons, including parvalbumin positive (PV+) fast-spiking interneurons [125]. Thus,
observed neurophysiological alterations in FXS humans and FMR1 KO mice may reflect failures of
PV+ neurons to mediate gamma oscillations. Phasic variation in gamma power in association cortex is
known to regulate crucial cognitive functions in mice and humans, and thus alterations in gamma band
neurophysiology we observe may contribute to cognitive deficits, including executive dysfunction,
in FXS [126,127]. For example, high background gamma in FXS may restrict the neural system’s
ability to send high gain signals to alert a change in behavior is needed. Studies of individuals with
schizophrenia and mouse models of this disorder have documented the association between PV+
interneuron dysfunction and altered gamma oscillations and EF deficits, including those in working
memory and cognitive flexibility [125,127–131]. This provides evidence of failure to phasically increase
gamma oscillations needed to perform EF functions due to saturated background gamma activity. Still
future translational studies are needed determine if or how well-documented EEG abnormalities of
both local and long-distance connections are related to EF deficits in individuals with FXS as well as
FMR1 KO mouse models, as this is critical for drug discovery and novel treatment development.
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4. Crucial Considerations
The >50 studies of EF in FXS reviewed were completed across a wide range of IQ levels (male: 30–82;
female: 46–112) and ages (1–75 years), included both single and co-ed sex samples, and used many
different EF measures. Though important findings have emerged with new insights in potential
component processes underlying EF deficits in FXS, inconsistences across studies still limit our ability
to interpret these findings. Multiple crucial methodological issues and confounding factors that could
have affected EF performance in individuals with FXS are addressed, with suggestions for future work
in this area.
4.1. FXS Sample Characteristics
The inclusion of a wide spectrum of ability levels and ages in EF studies of FXS helps capture
the breadth of behavioral and cognitive presentations in this patient population, but also likely
confounded findings by potentially washing out effects within specific subgroups of individuals.
Factors such as medication usage and co-occurring diagnoses also likely confounded EF performance in
individuals with FXS. For example, stimulants may have improved certain aspects of EF like attention,
processing speed, and inhibitory control, whereas atypical antipsychotics and benzodiazepines
may have punitively impacted aspects of EF like processing speed, attention, working memory,
and inhibitory control as previously shown [132]. Yet, the majority of studies did not provide data
on medication usage for FXS participants (or control groups), and among those studies that did,
medication classes were not specified. This makes interpreting findings challenging, especially as
some studies showed on-medication participants performed better than those off-medication [56],
while others found the opposite trend [31]. Only three studies excluded for psychotropic medication,
which is reasonable given known effects on EF [16,41,50]; however, medication-naïve studies are
neither representative or feasible in the FXS population. Thus, it is critical for future studies to address
potential confounds of medication usage on performance as well as specifically examine performance
by medication class when possible within FXS participants.
Furthermore, few studies reported or accounted for co-occurring conditions in FXS participants.
Because co-occurring conditions like ASD and ADHD likely arise from the FMRP deficit, it is difficult to
determine the extent to which the pathophysiological processes underlying EF deficits overlap or differ
from those underlying these neurodevelopment disorders, which have their own well-documented
EF deficits (for review see [133,134]). It also is possible that affected component cognitive processes
clinically manifest as both EF deficits and behavioral presentations of these co-occurring conditions
or that the observed EF deficits may reflect cognitive traits of other genetic liabilities superimposed
upon the FXS phenotype [135,136]. Though the mechanisms remain unknown, it is not surprising that
numerous studies indicated EF deficits worsened with more severe ASD symptoms in individuals
with FXS [31,35,36,63,64]. Two previous studies excluded participants with DSM-IV diagnoses and
one specifically excluded for ASD [32,46,61], though the majority of previous studies did not take ASD
of ADHD symptomatology into account (i.e., using clinical variable as covariate) when assessing for
EF deficits. Thus, this latter approach as well as comparing EF performance in FXS participants with
and without ASD (or ADHD) may be important considerations for future studies.
4.2. Control Group Selection
In addition to highly variable patient groups, previous studies also were highly variable in their
choice of comparison control groups. Using a CA control group was not common (n = 12) among
studies, as it simply compares groups that by definition operate at different developmental levels.
Using a CA control group still may be appropriate in initial studies characterizing how EF in FXS
differs from typical development, as done in the majority of structural and functional brain imaging
studies in FXS [26,49,60]. In contrast, using an MA control group was the most common approach in
previous studies (n = 21). Yet, using a MA control group is based on the assumption that acquisition of
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skills and performance on target variables should be similar between groups despite not matching
on CA [137]. However, previous studies demonstrated that developmental profiles of EF often differ
between individuals with FXS and MA controls [31], contradicting the assumption. This is especially
problematic in a case when a 30-year old FXS participant with a mental age of five years is matched to
a six-year old control participant with a similar mental age. Due to possible confounds of maturation
and history effects, it would be difficult to determine, for example, whether the absence of a deficit
was due to compensatory processes developed over time in the individual with FXS [26,49,60] or
whether the presence of a deficit only appeared at certain chronological ages as implicated by some
prior findings [31,50]. Another assumption put into question is whether overall MA is representative
of current functioning, as van der Molen and colleagues showed that EF performance varied based
on whether verbal or nonverbal MA was used in comparison [32]. This suggests previous studies
using combined MA comparison group may have over- or under-estimated EF deficits in FXS. Taken
together, CA and MA control groups each have their own pitfalls, many of which are difficult to avoid.
Matching on both mental and chronological age is the ideal option; however, is not always feasible
from a recruitment standpoint, and it is often unclear which types of comparison disabilities should be
utilized (e.g., Down syndrome, iDD, etc.).
Additionally, similar issues also arose in studies using iDD or syndromic control groups. Studies
widely varied on whether these groups were matched (if at all) on chronological age, mental age,
or IQ. The critical problem here is that it assumes differences on target variables are genuine difference
between syndromic groups rather than confounds such as differences in developmental trajectory
or brain maturation rate. Though using iDD or syndromic control groups carry many advantages,
including determining the specificity of findings, additional caution should be made when interpreting
findings in future studies that do not control for additional aspects. Overall, choosing appropriate
control groups is extremely challenging in FXS studies as usually the most ideal group often is not
feasible. Careful consideration and acknowledgment of potential confounds related to control groups
is recommended in future studies as these decisions may limit implications of findings.
4.3. Measures
The majority of measures chosen to assess EF in FXS were either part of a common
neurophysiological battery (e.g., Woodcock Johnson III, Wechsler tests) or adapted from these
more traditional measures (e.g., day/night task adaptation of Stroop). Many studies also chose
commonly used measures that do not have standardized versions (e.g., n-back, antisaccade, go/no-go),
and less frequently, studies created new experimental measures [62,64]. Independent of domain
or type of measure used, individuals with FXS had reduced completion rates compared to CA
and MA controls, especially among males with FXS. However, a smaller percentage of FXS
participants completed verbal and nonverbal working memory measures compared to measures of
inhibitory control [14,16,22,26,31,34,35,52,53,56,57,59], attention [15,18,19,50,52,56,63], and processing
speed [22,31,35,56]. Working memory completion rates were highly dependent on task complexity,
with higher load tasks with lower completions rates than lower load tasks [22,31,32], consistent with
findings demonstrating worse performance as complexity increased. A similar finding was observed
in studies using selective attention measures [56]. Cognitive flexibility and planning measures had
among the lowest completion rates (e.g., <30%; [22,23,31,46,48,55]). Of note, individuals who did
not complete measures were more likely to have lower MA, higher autistic symptomology, and not
taking psychotropic medication [14,22,23,35,63]. This suggests previous studies only captured EF
performance in a smaller subset, and perhaps less representative sample, of individuals with FXS. Thus,
given the high rate of failures across EF measures, this suggests development of more appropriate
measures is needed for individuals with FXS.
Traditional neuropsychological measures have many benefits, including verified psychometric
properties, published normative data, and standardization of administration and scoring procedures.
Still the vast majority of these measures are not be suitable for the FXS population due to heightened
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floor effects and task complexity as well as lack of normative data for developmental delay
populations [138,139]. In fact, completion rates were lowest among standardized measures compared
to adapted or experimental measures. Additionally, many traditional neuropsychological measures
assessed multiple domains of executive function simultaneously, making it difficult to determine
component processes impaired. For example, the Wisconsin Card Sorting Task (and other dimensional
sorting tasks) is primarily a measure of cognitive flexibility; however, working memory is necessary
to keep the current rule online, inhibition of distractors and prepotent responding is required to
limit perseverative and non-perseverative responses, and both selective and sustained attention are
important in selecting responses and staying on task, respectively. Thus, poor performance on the task
may be less specific to cognitive flexibility deficits in FXS, but may be due to, in part, other aspects of
executive dysfunction. Lastly, many traditional measures often heavily depend on verbal instructions
and sometimes even verbal responses, which increases potential confounding factors in this disorder
with prominent expressive and receptive language deficits. Overall, the psychometric advantages
of traditional neuropsychological measures may not outweigh the challenges associated with using
these measures in FXS participants. Thus, careful consideration should be made prior to choosing
standardized measures, especially in term of floor effects and specificity of findings.
Several studies examined feasibility of using standardized computer or application-based testing
batteries of executive function abilities, including NIH Toolbox, Cogmed Working Memory, and Kiddie
Test of Attentional Performance (KiTAP) [35,56,140]. These electronic batteries had distinct advantages
over more traditional neuropsychological batteries, including increased participant familiarity with
computer/tablet interface, flexibility in testing positions, button or touch response, limited verbal
demands, and increased motivation based on ‘game’ environment. Though developmental extensions
for two of the NIH Toolbox measures (e.g., dimensional change card test and flanker) were available for
FXS participants and allowed for higher completion rates and lower basals, psychometric properties
of the development extensions have not yet been established. This suggests the potential benefit of
modifying traditional measures to be more developmentally appropriate for this population, but more
studies are needed to confirm the validity of these measures. Though many of these measures did
not have such modifications, there still is promise in using batteries based on initial feasibility studies
based on findings of high test-retest reliability, convergent and divergent validity, and acceptability
among participants [35,56,140], especially when developmental modifications are available.
Less often, groups adapted standardized or non-standardized versions of EF measures to be
more child-friendly and appropriate for use in FXS participants or even rarer, developed their own
experimental measures [20,50,53,62,64,65,83]. Among these previous studies, common modifications
were implemented, including incorporating a simple story to increase engagement, using visually
appealing stimuli, and rewarding correct responses. Given the high levels of completion and reduced
floor effects among these studies, it suggests minor modifications may allow for the assessment of EF in
a wider range of FXS participants, consistent with findings from the modified versions of NIH Toolbox
measures. Though, test-retest reliability and other psychometric properties largely have not yet been
established for these performance-based measures, which is a critical aspect to measure selection,
especially within clinical trials. Taken together, modified measures appear to be the most appropriate
when examining EF in FXS, though the psychometric properties and sensitivity to change over time
longitudinally or in response to intervention warrant future study. Importantly, this suggests that the
majority of measures used in previous studies are not ideal for individuals with FXS and additional
work is needed to develop more appropriate measures of EF in this and similar patient populations.
4.4. Scoring and Analysis Method
One reason the majority of measures were not appropriate for individuals with FXS was because
adequate scores often could not be obtained from FXS participants due to floor effects. Though this
may be an effect of measure, it also suggests alternative scoring or analysis methods are needed when
assessing EF in this developmental disorder. Floor effects are well-documented in this population [138],
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which become particularly problematic when trying to track change over time or in response to
treatment, as a large range of low raw scores equate to the lowest standard score. Indeed, many studies
instead used raw scores, which has been recommended from several groups when assessing cognitive
functioning in this population [141]. Additionally, a promising method was developed to calculate
deviation scores based on raw scores in order to better capture cognitive performance in FXS by lowering
the floor of the Stanford-Binet fifth edition (SB-5) and Wechsler Intelligence Scale for Children-Third
Edition (WISC-III) [138,139]. For example, by expanding the floor of the SB-5, individuals with FXS
were noted to have significantly lower verbal working memory performance than was indicated by
standard scores, and it became a clear weakness as evidenced by being approximately six standard
deviations below the mean, relative to most other domains [138]. Yet, this deviation score approach
only has been applied to SB-5 and WISC-III thus far, warranting exploration of its use for other
neuropsychological measures of EF, especially as this may be an alternative solution to developing
new or modified measures.
In addition, choice of dependent variable is an important consideration when assessing EF in
FXS. The majority of studies used one or two variables (e.g., reaction times and correct response rates)
to quantify performance, which could greatly simplify the complex processes assessed during EF
measures. As a result, relevant factors could be overlooked and thus impede our understanding of
mechanisms underlying impairments. For example, categorizing error types proved useful in multiple
studies as it showed individuals with FXS had a propensity towards repetitive, or perseverative
responding, during distractor interference, cognitive flexibility, and selective attention measures that
was not observed in other syndromic disorders like DS and WS [18,19,46,52]. Thus, consideration of
additional relevant variables that may better reflect component processes may be important for future
EF studies in FXS. Additionally, choice of dependent variable (and measure) is critical to consider in
the context of clinical trials in its ability to detect real change when it occurs amid other factors leading
to variability/improvement. Relatedly, it also is important to consider whether certain measures and
dependent variables reflect more meaningful clinically significant changes as opposed to statistically
significant changes. However, our review of the literature demonstrates we remain limited in this
regard and future studies helping to determine these answers are critically needed.
4.5. Lack of Analogous Paradigms in Translational Studies of Rodent Models of FXS
In order to better understand the mechanistic bridge from gene to behavior in FXS, it is important to
examine EF performance in FMR1 KO mouse models of FXS during translational behavioral measures.
The development of clinically- and biologically-relevant behavioral assays comparable to those used in
humans is an area that warrants further consideration. Though tests of anxiety, seizure susceptibility,
sensorimotor gating, sociability, and sensory hypersensitivity have been readily implemented in
FXS rodent models, few have explored executive dysfunction [126]. Moreover, no study to date has
examined EF performance in both species using parallel measures. Previous studies have documented
EF deficits in FMR1 KO mice, though findings are more variable than those found in human studies.
Additionally, measures used in rodent students often are not analogous to those used in human studies.
For example, several studies have reported mild to absent working memory and cognitive flexibility
deficits in FXS rodent models [142–144] despite the consistency of these findings in FXS humans.
One possible explanation for inconsistent findings across species is the use of the Morris water maze to
assess nonverbal (spatial) working memory in FMR1 KO mice [142,145], for which there is no human
equivalent. In addition, absence of findings in mice may have been due, in part, to relatively intact
nonverbal working memory in FXS humans compared to verbal working memory, especially when
cognitive load is low, suggesting Morris water maze may be too easy for the mice to complete.
On the other hand, during a five-choice serial reaction time task [146], FMR1 KO mice show
quicker response times, more false alarms, and more perseverative responding compared to WT mice
during reversal trials [147,148]. Yet, perseverative responding normalized with successive training in
FMR1 KO mice, suggesting behavioral intervention similarly may help reduce perseverative behavior
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in individuals with FXS. Krueger and colleagues [149] also reported increased cognitive flexibility
errors during a spatial discrimination reversal learning task in FMR1 KO mice (though error type was
not specified). Thus, difficulty extinguishing a previously rewarded stimulus is consistent with findings
from FXS participants during measures of distractor interference, cognitive flexibility, and selective
attention, and suggests perseverative responding may be relatively conserved across species.
Additionally, Krueger and colleagues [149] reported that cognitive flexibility errors were associated
with decreased synaptic markers in orbitofrontal and medial prefrontal cortices, and that reductions in
postsynaptic proteins preceded expression of cognitive flexibility impairments. These findings suggest
a potential causal link between loss of FMRP expression in the PFC and cognitive dysfunction that
has only previously been implicated in human imaging studies. Given evidence of the selectivity of
specific cognitive flexibility errors in FXS as well as potential insights into gene to behavior pathways,
development of parallel measures in individuals with FXS and mouse models may be particularly
important. For example, analogous reversal learning paradigms have been used in individuals with
ASD and BTBR mouse models of ASD and have identified similar cognitive flexibility deficits in
both species [108,149,150]. Currently, our group is piloting the same measure in individuals with
FXS, with preliminary findings suggesting increased perseverative errors compared to CA controls
(unpublished). This ongoing work in collaboration with groups studying FMR1 KO mice may be
critical to the development of translational biomarkers in FXS. Though examining EF deficits in FMR1
KO mice is still in its infancy, previous studies offer promising findings that suggest the importance of
this area in future research.
5. Conclusions and Future Directions
Previous studies have begun to characterize EF deficits in FXS as well as provide evidence
linking FMRP expression to frontal-striatum-parietal-cerebellum circuitry and, ultimately, executive
dysfunction. Our review also highlighted that perseverative responding emerged as one the most
consistent findings across measures and most specific to FXS. Yet, critical gaps in our mechanistic
understanding of these deficits remain. A focused effort on developing translational measures that
can be used across species and methods (i.e., behavioral, EEG), is selective towards one EF domain or
cognitive process, and minimizes undue burden on the FXS participant is critical to bridging this gap.
By advancing our understanding of the pathophysiological processes underlying EF deficits in FXS,
as a field we will be better-suited to target EF in treatment studies. Outcome measurement of EF in
FXS clinical trials remains in its infancy. Though some traditional neuropsychological measures have
demonstrated high test-retest or reproducibility in this patient population (for complete list of measures
see [141]), individuals with FXS showed improvement only one measure (i.e., RBANS List Learning)
following open label treatment trial with lithium [151]. Still authors even reported that the cognitive
battery was too difficult for most FXS participants to complete, suggesting the measures chosen were
not appropriate for FXS participants, especially in the context of clinical trials. A recent review of
outcome measures suggested potential outcomes measures in FXS treatment studies [152], including
specific KiTAP and Woodcock–Johnson subtests. However, these measures only have been used in FXS
during initial feasibility studies [56], suggesting studies are needed to confirm their appropriateness in
this patient population, especially during treatment trials. Thus, as a field it is important to critically
examine the state of literature, and focus future work on identifying (or developing) measures of EF
with high test-retest reliability and construct validity that also link to hypothesized neurobiological
mechanisms as this would allow for greater potential of success in future clinical trials.
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